Valuation: Telix Pharmaceuticals Limited

Market Cap 5.31B 3.8B 3.26B 3.05B 2.79B 5.24B 364B 36.03B 14.05B 183B 14.28B 13.97B 605B P/E 2026 *
238x
P/E 2027 * 162x
Enterprise Value 5.74B 4.11B 3.52B 3.3B 3.02B 5.66B 393B 38.94B 15.19B 198B 15.44B 15.1B 654B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 3.68x
Free-Float
83.35%
Yield 2026 *
-
Yield 2027 * -
1 day-10.13%
1 week-10.02%
Current month+9.92%
1 month+3.44%
3 months+11.57%
6 months+49.76%
Current year+39.46%
1 week 15.62
Extreme 15.62
18.13
1 month 13.95
Extreme 13.95
18.13
Current year 8.26
Extreme 8.26
18.13
1 year 8.26
Extreme 8.26
19.07
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Date Insider Type Main position Quantity % Market Cap.
11/6/25 A Fiscal year

Founder

100,708 0.0298%
6/17/25 A Free

Founder

2,595 0.0008%
6/17/25 A Free

Founder

166,483 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-10.13%-10.02%-7.68%+58.10% 4.2B
+1.09%+5.26%+4.44%+26.03% 51.22B
-1.30%+2.20%+470.70%+596.99% 45.38B
+1.68%+8.08%+19.62%+91.50% 41.97B
+1.68%+9.70%+40.04%+21.12% 42.15B
-0.93%-4.80%+17.39%+46.60% 31.95B
-0.65%+3.04% - - 16.73B
+1.37%+7.55%+37.24%+152.94% 17.1B
+0.03%+3.91%+5.84%+35.04% 14.76B
+1.35%+5.75%+91.63%+47.40% 13.91B
Average -0.59%+2.88%+75.47%+119.52% 27.94B
Weighted average by Cap. +0.34%+3.08%+101.36%+147.27%

Financials

2026 *2027 *
Net sales 1.37B 984M 843M 788M 722M 1.35B 94.11B 9.31B 3.63B 47.28B 3.69B 3.61B 156B 1.58B 1.13B 969M 907M 830M 1.56B 108B 10.72B 4.18B 54.39B 4.25B 4.16B 180B
Net income 25.08M 17.98M 15.4M 14.41M 13.19M 24.75M 1.72B 170M 66.39M 864M 67.51M 66.04M 2.86B 19.93M 14.29M 12.24M 11.45M 10.48M 19.67M 1.37B 135M 52.75M 687M 53.64M 52.47M 2.27B
Net Debt 429M 308M 264M 247M 226M 424M 29.45B 2.91B 1.14B 14.8B 1.16B 1.13B 48.94B 498M 357M 306M 286M 262M 492M 34.16B 3.38B 1.32B 17.16B 1.34B 1.31B 56.75B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
21/08/26 A$15.62 -10.13% 4,587,381
20/08/26 A$17.38 +3.21% 5,205,523
19/08/26 A$16.84 +0.48% 974,002
18/08/26 A$16.76 +1.88% 2,024,589
17/08/26 A$16.45 -1.67% 1,279,956
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
15.62AUD
Average target price
23.44AUD
Spread / Average Target
+50.04%

Quarterly revenue - Rate of surprise